Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Yoon Cheah

Blood (2023) 142 (Supplement 1): 327.

https://doi.org/10.1182/blood-2023-179541

Published: 2023

Journal Articles

Infection Outcomes and Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Treated with Immunoglobulin Replacement Therapy

Jacob Soumerai, Thais Gift, Zaid Yousif, Raj Desai, Lynn Huynh, Gregory Belsky, Mei Sheng Duh, Marie Sanchirico

Blood (2023) 142 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2023-179458

Published: 2023

Journal Articles

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 738.

https://doi.org/10.1182/blood-2023-180069

Published: 2023

Journal Articles

Predicted Functional Consequences of TP53 Alterations and Prognosis in TP53 -Mutated Mantle Cell Lymphoma

Manik Uppal, Erel Joffe, Kurt S. Bantilan, Gilles Salles, Jacob Soumerai, Andrew D. Zelenetz, Anita Kumar

Blood (2023) 142 (Supplement 1): 3006.

https://doi.org/10.1182/blood-2023-187599

Published: 2023

Journal Articles

Infection Outcomes and Hypogammaglobulinemia in Patients with Non-Hodgkin Lymphoma Treated with Immunoglobulin Replacement Therapy

Jacob Soumerai, Zaid Yousif, Thais Gift, Raj Desai, Lynn Huynh, Caitlin Haven, Mei Sheng Duh, Marie Sanchirico

Blood (2023) 142 (Supplement 1): 3040.

https://doi.org/10.1182/blood-2023-187068

Published: 2023

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Blood (2023) 142 (Supplement 1): 330.

https://doi.org/10.1182/blood-2023-179529

Published: 2023

Journal Articles

Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia.

Thea Ioakimidis, MS, Christopher J Patterson, Zachary Hunter, Jacob Soumerai, Robert Manning, Diane L. Warren, Irene Ghobrial, M.D., Patricia Sheehy, NP, Steven Treon, MD, PhD

Blood (2009) 114 (22): 4789.

https://doi.org/10.1182/blood.V114.22.4789.4789

Published: 2009

Journal Articles

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia

Blood (2009) 113 (3): 626–634.

https://doi.org/10.1182/blood-2007-10-116848

Published: 2009

Journal Articles

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Steven Treon, MD, PhD, Andrew Branagan, Leukothea Ioakimidis, PhD, Jacob Soumerai, Christopher Patterson, MD, Parveen Wasi, MD, FRCP(C), Christos Emmanouilides, MD, PhD, Stanley R. Frankel, MD, T. Andrew Lister, MD, Pierre Morel, MD, Jeffrey Matous, MD, Stephanie A. Gregory, MD, Eva K. Kimby, MD, PhD

Blood (2008) 112 (11): 3057.

https://doi.org/10.1182/blood.V112.11.3057.3057

Published: 2008

Journal Articles

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

Irene M. Ghobrial, M.D., Stacey Chuma, RN, Amy Sam, Renee Leduc, Marybeth Nelson, PA, Kelly O’Connor, Brianna Harris, Jacob Soumerai, Diane Warren, Eric Jacobsen, MD, Daniel DeAngelo, MD, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Thomas E. Witzig, MD, Steven P. Treon, MD, PhD

Blood (2008) 112 (11): 1011.

https://doi.org/10.1182/blood.V112.11.1011.1011

Published: 2008

Journal Articles

Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia.

Leukothea Ioakimidis, PhD, Christopher Patterson, MD, Jacob Soumerai, Robert Manning, Patricia Sheehy, NP, Steven Treon, MD, PhD

Blood (2008) 112 (11): 2011.

https://doi.org/10.1182/blood.V112.11.2011.2011

Published: 2008

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, M.D., Jeffrey Matous, MD, Swaminathan Padmanabhan, MD, Ashraf Badros, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc1, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 832.

https://doi.org/10.1182/blood.V112.11.832.832

Published: 2008

Journal Articles

Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Xavier Leleu, Nancy Rubin, Marybeth Nelson, Renee Leduc, Diane Warren, Jana Allen, Sue Lovecchio, Jacob Soumerai, Peter Sportelli, Robert Birch, Craig Henderson, Steven P. Treon, Paul Richardson, Kenneth C. Anderson

Blood (2007) 110 (11): 4493.

https://doi.org/10.1182/blood.V110.11.4493.4493

Published: 2007

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Swaminathan Padmanabhan, Ashraf Badros, Marybeth Nelson, Renee Leduc, Xavier Leleu, Diane Warren, Jacob Soumerai, Ann Birner, Robert Schlossman, Nikhil Munshi, Paul Richardson, Steven P. Treon, Kenneth C. Anderson

Blood (2007) 110 (11): 4494.

https://doi.org/10.1182/blood.V110.11.4494.4494

Published: 2007

Journal Articles

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Renee Leduc, Marybeth Nelson, Xavier Leleu, Eric Jacobsen, Ann LaCasce, Daniel DeAngelo, David Fisher, Jennifer R. Brown, Robert Schlossman, Diane Warren, Jacob Soumerai, Kelly O’Connor, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson, Thomas E. Witzig, Steven P. Treon

Blood (2007) 110 (11): 4496.

https://doi.org/10.1182/blood.V110.11.4496.4496

Published: 2007

Journal Articles

IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM).

Zachary Hunter, Xavier Leleu, Evdoxia Hatjiharissi, Daniel Santos, Lian Xu, Alan Ho, Vinod Bakthavachalam, Anne-Sophie Moreau, Kelly O’Connor, Jacob Soumerai, Christopher Patterson, Irene Ghobrial, Susanna Hamilton, Sigitas Verselis, Edward Fox, Steven Treon

Blood (2006) 108 (11): 228.

https://doi.org/10.1182/blood.V108.11.228.228

Published: 2006

Journal Articles

Abnormal Expression of TRAF Adapter Proteins in Waldenstrom’s Macroglobulinemia.

Xavier Leleu, MD, Lian Xu, Zachary R. Hunter, Anne-Sophie Moreau, MD, Xiaoying Jia, Garrett O’Sullivan, Vinod Bakthavachalam, Allen W. Ho, Evdoxia Hatjiharissi, MD, Hai T. N’Go, Daniel D. Santos, MD, Kelly O’Connor, Robert Manning, Jacob Soumerai, Christopher Patterson, Irene M. Ghobrial, MD, Steven P. Treon, MD

Blood (2006) 108 (11): 4640.

https://doi.org/10.1182/blood.V108.11.4640.4640

Published: 2006

Journal Articles

Endoplasmic Reticulum Stress Is a Target for Therapy in Waldenstrom’s Macroglobulinemia (WM).

Xavier Leleu, MD, Lian Xu, Zachary R. Hunter, Xiaoying Jia, Anne-Sophie Moreau, MD, Allen W. Ho, Evdoxia Hatjiharissi, MD, Hai N’Go, Daniel D. Santos, MD, Kelly O’Connor, Robert Manning, Jacob Soumerai, Christopher Patterson, Irene M. Ghobrial, MD, Steven P. Treon, MD

Blood (2006) 108 (11): 4641.

https://doi.org/10.1182/blood.V108.11.4641.4641

Published: 2006

Journal Articles

Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom’s Macroglobulinemia (WM).

Christopher J. Patterson, BS, Anne Sophie Moreau, MD, Xavier Leleu, MD, Jacob Soumerai, BS, Zachary Hunter, BS, Evdoxia Hatjiharissi, MD, Lian Xu, BS, Steven Treon, MD, PhD

Blood (2006) 108 (11): 4749.

https://doi.org/10.1182/blood.V108.11.4749.4749

Published: 2006

NARROW

Infection Outcomes and Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Treated with Immunoglobulin Replacement Therapy

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Predicted Functional Consequences of TP53 Alterations and Prognosis in TP53 -Mutated Mantle Cell Lymphoma

Infection Outcomes and Hypogammaglobulinemia in Patients with Non-Hodgkin Lymphoma Treated with Immunoglobulin Replacement Therapy

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia.

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia.

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM).

Abnormal Expression of TRAF Adapter Proteins in Waldenstrom’s Macroglobulinemia.

Endoplasmic Reticulum Stress Is a Target for Therapy in Waldenstrom’s Macroglobulinemia (WM).

Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom’s Macroglobulinemia (WM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only